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Abstract: Quorum sensing (QS) antagonists have been proposed as novel therapeutic agents
to combat bacterial infections.
We previously reported that the secondary metabolite
0
3-methyl-N-(2 -phenylethyl)-butyramide, produced by a marine bacterium identified as Halobacillus
salinus, inhibits QS controlled phenotypes in multiple Gram-negative reporter strains. Here we
report that N-phenethyl hexanamide, a structurally-related compound produced by the marine
bacterium Vibrio neptunius, similarly demonstrates QS inhibitory properties. To more fully explore
structure–activity relationships within this new class of QS inhibitors, a panel of twenty analogs
was synthesized and biologically evaluated. Several compounds were identified with increased
attenuation of QS-regulated phenotypes, most notably N-(4-fluorophenyl)-3-phenylpropanamide
against the marine pathogen Vibrio harveyi (IC50 = 1.1 µM). These findings support the opportunity to
further develop substituted phenethylamides as QS inhibitors.
Keywords: quorum sensing; Vibrio; phenethylamide

1. Introduction
Bacterial populations synchronize gene expression via the release, detection, and biochemical
response to small signaling molecules called autoinducers [1,2]. In the case of pathogenic bacteria,
this chemical communication process, also referred to as quorum sensing (QS), coordinates phenotypes
such as production of virulence factors, biofilms, and swarming motility [3–7]. Hence, interference
with QS pathways provides an opportunity to attenuate pathogenicity, thereby representing a novel
mechanism for battling bacterial infections [8–11]. Furthermore, several studies have demonstrated
increased susceptibility of pathogenic bacteria to antibiotics when used in combination with QS
inhibitors [12,13].
Natural product investigations have yielded structurally distinct quorum sensing inhibitors
(QSIs), such as the brominated furanones isolated from the marine red alga Delisea pulchra [14,15]
and the γ-lactone, plakofuranolactone, isolated from the marine sponge Plakortis cf. lita [16]. Marine
organisms, including plants, animals, and microorganisms, have proven to be a particularly rich
source of QSIs with diverse structures [17]. Moreover, synthetic modifications to many of these
naturally-occurring scaffolds have led to higher affinity antagonists against bacteria pathogens [18].
For example, the marine honaucins, isolated from the bloom-forming cyanobacterium Leptolyngbya
crossbyana, were found to inhibit QS signaling-dependent phenotypes in V. harveyi and an engineered
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2.2. Bioassay Testing
Compounds were tested in triplicate against three established QSI sensor strains [31].
V. harveyi causes disease in a variety of marine animals, especially shrimp [34], and has
been previously used in the discovery of QSIs [35–37]. V. harveyi BB120 responds to the
autoinducers 3-hydroxybutanoyl-L-homoserine lactone (HBHL) AI-1, the furanosyl borate diester AI-2,
and (S)-3-hydroxytridecan-4-one (CAI-1) to regulate a variety of bacteria behaviors [38]. C. violaceum is
a Gram-negative bacterium that produces violacein, an antibiotic purple pigment, under QS control
using the autoinducer N-hexanoyl-L-homoserine lactone (HHL) [39]. Finally, the panel was screened
for QSI activity using E. coli JB525, a mutant E. coli harboring the gfp plasmid pJBA132 linked to
the LuxI/R quorum sensing system of Vibrio fischeri. This sensor strain produces an unstable green
fluorescent protein (GFP) in response to exogenous C6 -C8 AHL autoinducers [40]. Broth dilution
assays with E. coli JB525 were conducted in the presence of 32 nM HHL, as we found this autoinducer
provided the most consistent results and was used as a positive control in a similar E. coli reporter
system [41].
Phenethylamide 3 inhibited V. harveyi bioluminescence (IC50 = 99 µM) and violacein production
by C. violaceum (ZOI = 14 mm), but lacked activity against E. coli JB525, demonstrating that modest
changes in the alkyl chain impacts the anti-QS activity (Table 1).
Table 1. Activity of natural products and their analogs against three reporter strains.

Compound

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23

V. harveyi
BB120

E. coli
JB525

C. violaceum
ATCC 12472

IC50 (µM)

Std. Dev.

IC50 (µg/mL)

Std. Dev.

Zone of Inhibition a (mm)

110
NA
99
89
NA
17
94
29
6.2
15
48
3.3
5.6
86
3.5
1.1
3.0
6.0
12
NA
>200
19
82

12

11
NA
NA
NA
NA
NA
NA
NA
5.2
NA
1.1
>200
32
>200
3.8
25
69
NA
>150
NA
NA
56
13

3.5

20
12
14
NA
21
NA
NA
NA
11
NA
22
12
9
NA
NA
9
NA
NA
NA
NA
NA
13 b
11

5.9
13
2.9
7.0
3.0
0.40
7.6
1.9
3.6
2.7
1.6
0.60
0.37
2.0
8.1

1.2
17

1.0
0.36
12
1.0
13
14

2.2
4.0

IC50 values greater than 500 were considered inactive and are designated as NA (no activity). a Zones of inhibition
determined for 500 µg/disc. b Includes 8 mm zone of growth inhibition followed by zone of no violacein production.

2.3. Analog Design and Biological Results
The structural simplicity of the phenethylamide QSIs, along with their variable activities
against three different sensor strains, encouraged the preparation of synthetic analogs to explore
structure–activity relationships. Specifically, a panel of analogs was designed to explore the effects of
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Figure 3. Bar graph showing green fluorescent protein (GFP) production (fluorescence) at various
Figure 3. Bar graph showing green fluorescent protein (GFP) production (fluorescence) at various
concentrations of antagonist (11) and agonist (OHHL). The inhibitory activity of 11 is surmounted
concentrations of antagonist (11) and agonist (OHHL). The inhibitory activity of 11 is surmounted by
by higher concentrations of OHHL agonist, consistent with an antagonist-agonist relationship.
higher concentrations of OHHL agonist, consistent with an antagonist-agonist relationship. The
The concentration of 11 is in µg/mL and OHHL in nM. There were significant effects of compound 11
concentration of 11 is in µg/mL and OHHL in nM. There were significant effects of compound 11
concentrations, OHHL concentrations and interactions (two-way ANOVA F23,71 = 342.3098, p < 0.0001,
concentrations, OHHL concentrations and interactions (two-way ANOVA F23,71 = 342.3098, p < 0.0001,
Supplementary Material Table S1). Standard deviation error bars are included in a 2D version of the
Supplementary Material Table S1). Standard deviation error bars are included in a 2D version of the
graph (Supplementary Material Figure S5).
graph (Supplementary Material Figure S5).

Growth curves were conducted on all of the diphenyl analogs of compound 9 (compounds
Growth curves were conducted on all of the diphenyl analogs of compound 9 (compounds 12–
12–19, Figure 2C) and N-phenylhexanamide (11) at 100 µM, which is well above the IC50 value of
19, Figure 2C) and N-phenylhexanamide (11) at 100 µM, which is well above the IC50 value of the
the compounds, to ensure that the observed inhibition of luminescence was not due to inhibition or
compounds, to ensure that the observed inhibition of luminescence was not due to inhibition or
delay in growth of V. harveyi by the analogs. None of the compounds demonstrated a delay in growth
delay in growth of V. harveyi by the analogs. None of the compounds demonstrated a delay in
(Supplementary Material Figures S1–S3). Additionally, a luminescence curve for compound 16—the
growth (Supplementary Material Figures S1–S3). Additionally, a luminescence curve for compound
16—the most active compound—demonstrated that the luminescence inhibition persists for the
duration of luminescence production by the untreated bacteria (Supplementary Material Figure S4).
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most active compound—demonstrated that the luminescence inhibition persists for the duration of
luminescence production by the untreated bacteria (Supplementary Material Figure S4).
3. Discussion
N-phenethyl hexanamide (3) was isolated from a marine V. neptunius strain and identified as a QSI
against the pathogen V. harveyi. To date, this is the first secondary metabolite reported for this bacteria
species. N-phenethyl hexanamide adds to a small group of previously described phenethylamide QSIs
produced by marine bacteria strains belonging to the genera Halobacillus [31,33] and Oceanobacillus [44],
and bears structural resemblance to cyclic dipeptide QSIs comprising phenylalanine [45]. These natural
products provided the motivation for synthesizing a panel of derivatives to more fully investigate
this QSI class. The simple structures facilitated rapid assembly, frequently in one synthetic step with
crystallization to prepare the desired pure product, further encouraging exploration of structure–activity
relationships for these cell–cell signaling antagonists.
Many analogs were more active than the natural product 1 in the V. harveyi assay, with several
compounds having IC50 values in the low micromolar range. In particular, diphenyl analogs appear
to be the most promising QSIs against V. harveyi, and four of these (9, 13, 16, and 23) demonstrated
activity against all three reporter strains. While a general QSI might be desirable for treating infections
caused by pathogens that use AHL-mediated signaling, it appears that the phenethylamide scaffold is
more easily modified to optimize activity against specific QS systems.
Substitution of phenethylamine with aniline yielded N-phenylhexanamide (11), which was the
only analog demonstrating equal or more potent activity than 1 against all three reporter strains.
Other groups have identified non-natural modulators of AHL-based QS in which the native homoserine
lactone moiety has been replaced with a phenyl ring, which suggests that the lactone moiety is not
necessary for receptor binding. For example, Smith et al. demonstrated that 2-(3-oxo-C12-amino)phenol
inhibits GFP production in a Pseudomonas aeruginosa strain constructed to express GFP in its LasR QS
circuit [23].
Taken together, our results suggest that further exploration of the diphenyl analogs of the
marine phenylethyl amide secondary metabolites (1–3) may yield more potent QSIs and highlights
the need for increased investigation of marine microbes for the discovery and development of new
anti-QS compounds.
4. Materials and Methods
4.1. Media
Bioassay media consisted of the following: (1) Marine broth (MB) containing 1 g yeast extract and
5 g peptone (Alpha Biosciences, Baltimore, MD, USA) per L synthetic seawater (Instant Ocean; 36 g per
L); (2) Luria–Bertani broth containing 4 g sodium chloride (LB4 ); and (3) nutrient broth (NB) containing
5 g yeast extract and 10 g tryptone per L DI H2 O. For agar media, 15 g agar per L of H2 O was used.
4.2. Reporter Strains
Vibrio harveyi BB120 [3] a wild-type, bioluminescent strain, was cultivated at 30 ◦ C in MB.
C. violaceum ATCC 12472 was cultured at 29 ◦ C with shaking in NB. E. coli JB525 is E. coli MT102
harboring the gfp plasmid pJBA132 and produces an unstable green GFP in response to C6-C8 AHL
autoinducers [40]. E. coli JB525 was cultured in LB4 at 30 ◦ C.
4.3. Isolation and Sequencing RIP07-147
The bacterial strain RIP07-147 (GenBank accession number MK821060) was isolated from
a suspended marine particle collected in August 2007 in the East Passage of Narragansett Bay,
Rhode Island, USA. The isolate was grown overnight at 24 ◦ C in YP media and DNA was extracted
using the DNeasy blood and tissue kit (Qiagen, Hilden, Germany) per the manufacturer’s protocol.
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PCR amplification of the bacterial 16S rRNA gene was accomplished using universal bacterial primers
27F and 1392R [46]. The isolate was identified based on 97.01% homology to V. neptunius strain LMG
20536 (22 February 2019) [47,48].
4.4. Co-Cultivation with V. harveyi BB120
An overnight culture of V. harveyi BB120 was diluted into 5 mL of molten MB soft agar at 40 ◦ C and
poured atop a MB agar plate. Two µL of an overnight culture of the test isolate, RIP07-147, was spotted
onto the V. harveyi lawn. The plate was incubated at 24 ◦ C overnight and imaged with a Typhoon 9410
variable mode imager (GE Healthcare Bio-Sciences, Piscataway, NJ, USA) in chemiluminescence mode.
Zone of no light bioluminescence was measured to the nearest mm.
4.5. Isolation of N-Phenethyl Hexanamide
RIP07-147 was inoculated on yeast and peptone (YP) agar media in three 16 × 30 cm aluminum
pans. The pans were incubated at 24 ◦ C for 48 h. The agar was then extracted with ethyl acetate,
filtered, and the liquid portion concentrated in vacuo. The extract was adsorbed onto C18 resin
and fractionated by vacuum liquid chromatography with step-wise gradients of 100% water to 100%
methanol (20% methanol increments) with a final acetone wash. Using the V. harveyi BB120 assay
(see below), the active constituent was determined to be in the 60% and 80% methanol fractions.
These fractions were combined and further purified by HPLC (Waters Xterra RP18 19 × 100 mm, 20 to
80% methanol over 30 min at 5 mL/min) to yield 3 as the single active compound. Compound 3 was
identified as N-phenethyl hexanamide by comparison of 1 H NMR spectroscopy and mass spectrometry
data in comparison with literature data [33].
4.6. Bioassays
4.6.1. V. harveyi BB120 Broth Dilution Assay
An overnight culture of V. harveyi BB120 in MB was diluted (OD600 = 0.1), and 200 µL of the
diluted culture was added to 10 mL of MB. One µL of test compounds dissolved in DMSO at 50 mg/mL
was added to a 96-well clear bottom, white microtiter plate (Corning, 0.5% DMSO final concentration).
The diluted cell culture was added to the wells of the opaque microtiter plate and incubated at 30 ◦ C
with shaking for 5 h. The plates were read on a SpectraMax Multimode Microplate Reader (Molecular
Devices, Sunnyvale, CA, USA). Relative luminescence units (RLU) were normalized by the OD600
values. Percent luminescence was calculated by defining the untreated cells (no compound) as 100%.
4.6.2. C. violaceum Disc Diffusion Assay
Disc diffusion assays were performed with pure compounds at 500 µg/disc. One hundred
microliters of overnight bacterial culture were added to 10 mL of NB, vortexed, and then 100 µL of the
diluted culture was spread atop an NB agar plate. Impregnated, sterile discs (6 mm) were laid onto
the test plates and incubated overnight. Zones of inhibition (ZOI), as indicated by lack of pigment
production, were measured to the nearest mm.
4.6.3. E. coli JB525 Bioassay
Inhibition of fluorescence was determined using a method modified from Teasdale et al. [31].
Briefly, an overnight culture of E. coli JB525 in LB4 broth was diluted (OD450 0.25) with fresh media.
Cultures were treated with 32 nM HHL and test compound ranging from 2 to 250 µg/mL (0.5%
final DMSO concentration in 200 µL) in a 96-well clear bottom, black microtiter plate. To determine
antagonist–agonist relationships, each serial dilution of test compound (8–1000 µM) was challenged
with each increasing OHHL concentration (16–512 nM) in three biologically separate replicates (0.7%
DMSO final concentration). Plates were incubated with shaking at 30 ◦ C for 3 h. Fluorescence was
detected with an excitation at 475 nm and emission at 515 nm on the SpectraMax i3 multi-mode
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microplate reader (Molecular Devices, Sunnyvale, CA, USA). Growth was evaluated after 3 h by optical
density at 450 nm. Fluorescence values were normalized by optical density. For IC50 determination
at 32 nM HHL, percent fluorescence was determined by defining control wells with 32 nM HHL as
100% fluorescence.
4.6.4. Statistical Analysis
Assays were performed in biological and technical triplicate. Data were analyzed using GraphPad
Prism 7. IC50 values were calculated using non-linear regression analysis and the values of each trial
were averaged for the final reported value.
4.7. Chemical Syntheses
1H

NMR spectra were recorded on a Bruker Avance (300 MHz) or a Bruker Biospin (400 MHz)
spectrometer and mass spectra were recorded on a SCIEX QTOF 4600 using flow injection in 75%
aqueous CH3 OH containing 0.1% HCOOH. All reagents and compounds were purchased from
Sigma-Aldrich or Acros Chemicals. Purification of the desired products was accomplished by either
recrystallization (ethyl acetate and hexane), automated column chromatography on silica (CombiFlash,
Teledyne Isco, Lincoln, NE, USA) using a linear gradient of hexanes in ethyl acetate (0%–100%), or by
reverse-phase HPLC (Waters X-Terra Prep RP18 column, 19 × 100 mm, gradient of MeOH in H2 O (0.1%
formic acid, 5 mL/min). HPLC was performed on a Waters 600 with a 2487 dual wavelength detector
set to λ 220 nm and λ 254 nm. Compounds were synthesized as follows.
4.7.1. General Procedure for Coupling Reactions
The appropriate carboxylic acid in 50 mL acetonitrile was treated with HBTU
(N,N,N0 ,N0 -Tetramethyl-O-(1H-benzotriazol-1-yl)uranium
hexafluorophosphate)
(1.2
eq),
diisopropylethyamine (1.5 eq), and the requisite amine. The reaction was stirred overnight
at ambient temperature, concentrated in vacuo, and then partitioned between ethyl acetate and
0.1 M HCl. The organic phase was separated, sequentially washed with saturated sodium bicarbonate
and water, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The resulting
products were purified by either crystallization or chromatography as described. Percent yields ranged
from 30%–89%.
4.7.2. Synthesis and Characterization of Compounds 1–23
3-Methyl-N-(20 -phenylethyl)-butyramide (1). Iso-valeric acid and phenethylamine. Desired product was
purified by crystallization (white crystals). ESI-MS [M + H]+ = 206.15; 1 H NMR (400 MHz, CDCl3 ):
δ 0.92 (d, J = 8.0 Hz, 6H), 1.98 (d, J = 8.0 Hz, 2H), 2.07 (m, 1H), 2.82 (t, J = 6.8 Hz, 2H), 3.53 (m, 2H),
5.46 (s, 1H) 7.15–7.35 (m, 5H).
N-Phenethylhexanamide (3). Hexanoic acid (4 mmol, 1 eq) and phenethylamine (4 mmol, 1 eq). Desired
product was purified by HPLC (50%–75% MeOH in H2 O over 10 min, white solid). ESI-MS [M + H]+
= 220.17; 1 H NMR (400 MHz, CDCl3 ): δ 0.88 (t, J = 7.0 Hz, 3H), 1.29 (m, 4H), 1.59 (m, 2H), 2.09 (t,
J = 7.5 Hz, 2H), 2.82 (t, J = 7.0 HZ, 2H), 3.52 (m, 2H), 5.44 (s, 1H), 7.19 (m, 5H).
N-Phenethyldecanamide (4). Decanoic acid (5 mmol, 1 eq) and phenethylamine (5 mmol, 1 eq). Desired
product was purified by crystallization (white crystals). ESI-MS [M + H]+ = 276.12; 1 H NMR (400 MHz,
CDCl3 ): δ 0.88 (t, J = 8 Hz, 3H), 1.26 (s, 12H), 1.58 (t, J = 8 Hz, 2H), 2.11 (t, J = 8 Hz, 2H), 2.81 (t, J = 8 Hz,
2H), 3.51 (dt, J = 8 Hz, 2H), 5.61 (s, 1H), 7.18–7.32 (m, 5H).
N-Phenethylbutryamide (5). Butyric acid (4 mmol, 1 eq) and phenethylamine (4 mmol, 1 eq). Desired
product was purified by HPLC (50% MeOH in H2 O to 75% MeOH over 10 min, white solid). ESI-MS
[M + H]+ = 192.06; 1 H NMR (400 MHz, CDCl3 ): δ 0.91 (t, J = 7.5 Hz, 3H), 1.61 (m, 2H), 2.10 (t, J = 7.5 Hz,
2H), 2.81 (t, J = 7.5 Hz, 2H), 3.51 (m, 2H), 5.54 (s, 1H), 7.18–7.33 (m, 5H).
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N-Phenethyl-3-phenylpropanamide (6). Hydrocinnamic acid (4 mmol, 1 eq) and phenethylamine (4 mmol,
1 eq). Desired product was purified by crystallization (white crystals). ESI-MS [M + H]+ = 254.17;
1 H NMR (400 MHz, CDCl ): δ 2.43 (t, J = 6.8 Hz, 2H), 2.74 (t, J = 6.8 Hz, 2H), 2.95 (t, J = 6.8 Hz 2H),
3
3.48 (m, 2H), 5.42 (s, 1H), 7.04–7.31 (m, 10H).
N-Phenethyl-4-phenylbutanamide (7). 4-phenyl-butyric acid (5 mmol, 1 eq) and phenethylamine (5 mmol,
1 eq). Desired product was purified by crystallization (white crystals). ESI-MS [M + H]+ = 268.18;
1 H NMR (400 MHz, CDCl ): δ 1.95 (m, 2H), 2.13 (t, J = 7.0 Hz, 2H), 2.63 (t, J = 8.0 Hz, 2H), 2.82 (t,
3
J = 8.0 Hz, 2H), 5.46 (s, 1H), 7.14–7.33 (m, 10H).
3-Phenyl-N-(3-phenylpropyl) propanamide (8).
Hydrocinnamic acid (4 mmol, 1 eq) and
3-phenyl-1-propylamine (4 mmol, 1 eq). Desired product was purified by HPLC (50% MeOH
in H2 O to 75% MeOH over 10 min, white solid). ESI-MS [M+Na]+ = 290.03; 1 H NMR (400 MHz,
CDCl3 ): δ 1.77 (m, 2H), 2.43 (t, J = 8Hz, 2H), 2.57 (t, J = 8Hz, 2H), 2.95 (t, J = 8Hz, 2H), 3.25 (t, J = 8Hz,
2H), 5.32 (s, 1H), 7.13–7.30 (m, 10H).
N,3-Diphenylpropanamide (9). Hydrocinnamic acid (4 mmol, 1 eq) and aniline (4 mmol, 1 eq). Desired
product was purified by crystallization (white crystals). ESI-MS [M + H]+ = 226.04; 1 H NMR (400 MHz,
CDCl3 ): δ 2.66 (t, J = 8 Hz, 2H), 3.05 (t, J = 8 Hz, 2H), 7.10 (t, J = 8 Hz, 1H), 7.22–7.45 (m, 10H).
N,4-Diphenylbutanamide (10). 4-phenyl-butyric acid (4 mmol, 1 eq) and aniline (4 mmol, 1 eq). Desired
product was purified by crystallization (white crystals). ESI-MS [M + H]+ = 240.04; 1 H NMR (400 MHz,
CDCl3 ): δ 2.08 (m, 2H), 2.35 (t, J = 8 Hz, 2H), 2.72 (t, J = 8 Hz, 2H), 7.11 (t, J = 8Hz, 1H), 7.21–7.34 (m,
8H), 7.51 (d, J = 8 Hz, 2H).
N-Phenylhexanamide (11). Hexanoic acid (4 mmol, 1 eq) and aniline (4 mmol, 1 eq). Desired product
was purified by crystallization (white crystals, 89%). ESI-MS [M + H]+ = 192.14; 1 H NMR (400 MHz,
CDCl3 ): δ 0.91 (t, J = 6.5 Hz, 3H), 1.35 (m, 4H), 1.73 (m, 2H), 2.35 (t, J = 7.5 Hz, 2H), 7.26 (s, 1H), 7.10 (t,
J = 7.3 Hz, 1H), 7.31 (t, J = 8.0 Hz, 2H), 7.52 (d, J = 7.8 Hz, 2H).
N-4-Methoxyphenyl-3-phenylpropanamide (12). Hydrocinnamic acid and p-anisidine. Desired product
was purified by crystallization (pale purple crystals, 30%). ESI-MS [M + H]+ = 256.14; 1 H NMR
(300 MHz, CDCl3 ): δ 2.61 (t, J = 7.6 Hz, 2H), 3.75 (s, 3H), 3.02 (t, J = 7.7 Hz, 2H), 6.8 (d, J = 9Hz, 2H),
7.19–7.32 (m, 7H), 7.33 (bs, 1H).
N-Phenyl-3-(4-methoxyphenyl)-propanamide (13). 3-(4-methoxyphenyl) propanoic acid and aniline.
Desired product was purified by crystallization (white crystals, 31%). ESI-MS [M+Na]+ = 278.12;
1 H NMR (300 MHz, CDCl ): δ 2.59 (t, J = 7.6 Hz, 2H), 2.95 (t, J = 7.6 Hz, 2H), 3.76 (s, 3H), 6.80 (d,
3
J = 8.6 Hz, 2H), 7.13 (m, 3H), 7.26 (t, J = 7.0 Hz, 2H), 7.44 (d, J = 7.7 Hz, 3H).
N-4-Methoxyphenyl-3-(4-methoxyphenyl)-propanamide (14). 3-(4-methoxyphenyl) propanoic acid and
p-anisidine. Desired product was purified by crystallization (white crystals, 78%). ESI-MS [M+Na]+
= 308.13; 1 H NMR (300 MHz, CDCl3 ): δ 2.58 (t, J = 7.7 Hz, 2H), 2.95 (t, J = 7.6 Hz, 2H), 3.77 (s, 6H),
6.82 (d, J = 8.6Hz, 4H), 7.14 (d, J = 8.4 Hz, 2H), 7.34 (bs, 1H), 7.37 (d, J = 8.8 Hz, 2H).
N-Phenyl-3-(4-fluorophenyl) propanamide (15). 3-(4-fluorophenyl) propanoic acid and Aniline. Desired
product was purified by crystallization (white crystals, 51%). ESI-MS [M+Na]+i = 266.09; 1 H NMR
(300 MHz, CDCl3 ): δ 2.61 (t, J = 7.5 Hz, 2H), 3.00 (t, J = 7.5 Hz, 2H), 6.96 (t, J = 8.7 Hz, 2H), 7.13 (m, 2H),
7.28 (t, J = 7.9 Hz, 2H), 7.27 (d, J = 8.01 Hz, 2H), 7.44 (d, J = 7.8 Hz, 2H).
N-(4-Fluorophenyl)-3-phenylpropanamide (16). 4-fluoroaniline and hydrocinnamic acid. Desired products
were purified by crystallization (white crystals, 42%). ESI-MS [M+Na]+ = 266.09; 1 H NMR (300 MHz,
CDCl3 ): δ 2.62 (t, J = 7.6 Hz, 2H), 3.01 (t, J = 7.6 Hz, 2H), 6.94 (t, J = 8.7 Hz, 2H), 7.17–7.37 (m, 7H),
7.43 (bs, 1H).
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N-4-Fluorophenyl-3-(4-fluorophenyl) propanamide (17).
3-(4-fluorophenyl) propanoic acid and
4-fluoroaniline. Desired product was purified by crystallization (white crystals, 28%). ESI-MS
[M+Na]+ = 284.09; 1 H NMR (300 MHz, CD3 OD) δ 2.63 (t, J = 8.5 Hz, 2H), 2.95 (t, J = 7.6 Hz, 2H),
6.99 (m, 5H), 7.24 (dd, J = 8.6 Hz, 5.5 Hz, 2H), 7.49 (dd, J = 9.2 Hz, 4.9 Hz, 2H).
N-(4-Fluorophenyl)-3-(4-methoxyphenyl) propanamide (18). 3-(4-methoxyphenyl)propanoic acid and
4-fluoroaniline. Desired product was purified by crystallization (white crystals, 39%). ESI-MS [M+Na]+
= 296.11; 1 H NMR (300 MHz, CD3 OD): δ 2.63 (t, J = 7.6 Hz, 2H), 2.92 (t, J = 7.7 Hz, 2H), 3.74 (s, 3H),
6.82 (d, J = 8.7 Hz, 1H), 7.04 (t, J = 8.9Hz, 2H), 7.17] (d, J = 8.9 Hz, 1H), 7.65 (d, J = 9.2 Hz, 2H), 7.65 (d,
J = 9.2 Hz, 2H), 7.69 (bs, 1H).
N-(4-Methoxyphenyl)-3-(4-fluorophenyl) propanamide (19). 3-(4-fluorophenyl) propanoic acid and
p-anisidine. Desired product was purified by crystallization (pale purple crystals, 62%). ESI-MS
[M+Na]+ = 296.11; 1 H NMR (300 MHz, CDCl3 ): δ 2.63 (t, J = 7.6 Hz, 2H), 2.97 (t, J = 7.6 Hz, 2H), 3.75 (s,
3H), 6.84 (d, J = 9.0 Hz, 2H), 7.02 (t, J = 8.8 Hz, 2H), 7.28 (d, J = 8.4 Hz, 1H), 7.29 (d, J = 8.4 Hz, 1H),
7.53 (d, J = 9 Hz, 2H), 8.98 (bs, 1H).
N-(4-Iodophenyl)-3-phenylpropanamide (20). 4-Iodoaniline and hydrocinnamic acid. Desired product was
purified by crystallization (pale purple crystals, 40%). ESI-MS [M+Na]+ = 374.00; 1 H NMR (300 MHz,
CDCl3 ): δ 2.65 (t, J = 7.5 Hz, 2H), 3.05 (t, J = 7.5 Hz, 2H),6.92 (bs, 1H), 7.26 (m, 7H), 7.59 (d, J = 8.8 Hz,
2H).
3-(4-Bromophenyl)-N-phenylpropanamide (21). 3-(4-bromophenyl) propionic acid (4 mmol, 1 eq) and
aniline (4 mmol, 1 eq). Desired product purified by crystallization. ESI-MS [M+Na]+ = 325.88; 1 H NMR
(400 MHz, CDCl3 ): δ 2.63 (t, J = 7.5 Hz, 2H), 3.03 (t, J = 7.5 Hz, 2H), 7.10 (m, 4H), 7.26 (d, J = 8 Hz, 1H),
7.32 (t, J = 7 Hz, 2H), 7.44 (m, 3H).
3-(4-Hydroxyphenyl)-N-phenylpropanamide (22). Compound 12 (1 mmol) was dissolved in 2 mL DMF,
treated with iodocyclohexane (10 mmol), and refluxed under nitrogen for 14 h. The reaction was
then cooled, poured into water (20 mL), and extracted with ethyl acetate (3 × 20 mL). The organic
layer was washed sequentially with saturated aq. NaHSO3 and brine, dried over Na2 SO4 , filtered,
and concentrated. The crude product was purified by column chromatography (white solid, 54%).
ESI-MS [M+Na]+ = 264.10; 1 H NMR (300 MHz, CD3 OD): δ 2.61 (t, J = 7.0 Hz, 2H), 2.97 (t, J = 7.0 Hz,
2H), 8.9 (t, J = 7.7 Hz, 2H), 6.70 (d, J = 8.9 Hz, 2H), 7.25 (m, 5H), 7.25 (d, J = 9.0 Hz, 2H).
N-Phenyl-3-hydroxyphenylpropanamide (23). Prepared from 13 using identical method as for compound
22 and purified by column chromatography (white solid, 53%). ESI-MS [M + H]+ = 242.12; 1 H NMR
(300 MHz, CDCl3 ): d 2.62 (t, J = 7.6 Hz, 2H), 2.89 (t, J = 7.7 Hz, 2H), 6.75 (t, J = 8.6 Hz, 2H), 7.06 (m,
1H), 7.08 (d, J = 8.6 Hz, 2H), 7.27 (t, J = 7.9 Hz, 2 H), 7.64 (d, J = 7.6 Hz, 2H), 9.12 (bs, 1H).
Supplementary Materials: The following are available online at http://www.mdpi.com/1660-3397/17/7/389/s1,
Figures S1–S3: 24-h growth curves of V. harveyi in the presence of phenethylamide analogues, Figure S4:
24-h luminescence curves by V. harveyi BB120 in the presence of phenethylamide analogues 14 (100 µM) and 16
(10 µM) at concentrations that are above their IC50 values. Figure S5: 2D version of Figure 3 with error bars
added. Bar graph showing GFP production (fluorescence) at various concentrations of antagonist (11) and agonist
(OHHL). Error bars reflect at least three experiments each done in triplicates. Table S1: One-way ANOVA for
effect of Compound 11 concentration.
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